ESPR - NASDAQ
Esperion Therapeutics, Inc.
$3.14
+0.32%Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
At a Glance
Live Snapshotespr
Total Non-Current Assets
Last Annual Value
298.03M
3-Year CAGR
519%
5-Year CAGR
110%
10-Year CAGR
14%
Esperion Therapeutics, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Esperion Therapeutics, Inc. NASDAQ:ESPR | 298.03M | 297.9% | 41.5% | 25.1% | |
 SIGA Technologies, Inc. NASDAQ:SIGA | 6.61M | -24.5% | 2.0% | -23.1% | |
 Emergent BioSolutions Inc. NYSE:EBS | 656.10M | -16.9% | -17.2% | 3.6% | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 12.90M | -9.8% | -19.5% | 9.4% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 17.98M | 19.9% | 27.9% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 171.75M | -10.4% | -22.0% | 8.0% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 46.94M | 52.1% | 10.5% | N/A | |
 Absci Corporation NASDAQ:ABSI | 66.72M | -11.6% | -15.3% | N/A | |
 Orthofix Medical Inc. NASDAQ:OFIX | 433.80M | -4.9% | 15.9% | 9.3% | |
 Aquestive Therapeutics, Inc. NASDAQ:AQST | 11.16M | -12.1% | -5.4% | -3.6% |
Esperion Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ESPR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.